
    
      This is a phase 4, multicenter, randomized, double-blind, placebo-controlled, parallel-group
      interventional study comparing tolvaptan (15 to 60 mg) to placebo in adult patients
      hospitalized (or admission to emergency room) due to worsening of heart failure and
      dilutional hyponatremia. All patients will be on standard therapy for heart failure.
    
  